Aspirin or Clopidogrel as Monotherapy after 12 month DAPT

Original Title: Clopidogrel versus Aspirin as an Antiplatelet Monotherapy after 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents. Reference: Taek Kyu Park et al. Circ Cardiovasc Interv. 2016 Jan;9(1):e002816.

Courtesy of Dr. José Amadeo Guillermo Álvarez.

The use of dual antiplatelet therapy (DAPT) over 12 months after hospitalization for acute myocardial infarction (AMI) or drug eluting stent implantation (DES) could, in some subgroups of patients, reduce ischemic events at the expense of a higher risk of bleeding. However, no evidence supports a sound recommendation over the best antiplatelet after a 12 month DAPT treatment. This is an observational study carried out between 2003 and 2010 that compares the clinical evolution of 3243 patients receiving DES and 12 month DAPT. Patients were divided in two groups, those prescribed aspirin (n=2472) and those prescribed clopidogrel (n=771). Patients in the clopidogrel group had more comorbidities and more complex lesions than those in the aspirin group.

After a 36 month follow up, clopidogrel monotherapy resulted in a significant reduction of the final end point, the combination of death, AMI or stroke (aspirin vs. clopidogrel 3.8% vs 2.6% HR 0.54; CI 95% 0.32-0.92; p=0.02) and of cardiac mortality (aspirin vs. clopidogrel 1.4% vs 0.5%; HR 0.31; CI 95% 0.11-0.93; p=0.04). Major bleeding (TIMI) was similar in both groups (0.9% vs 1.3%; HR 1.03; CI 95% 0.46-2.32: p=0.95).

Conclusion
After 12 months of dual antiplatelet therapy, clopidogrel monotherapy instead of aspirin could be associated to a lower risk of ischemic events in patients receiving a DES.

Editorial Comment
We should bear in mind this registry did not randomize the administered drugs. Even though the population in the aspirin group has characteristics of lower clinical and angiographic risk, most of these patients received first generation DES (sirolimus or paclitaxel, 64.3%), whereas most of patients in the clopidogrel group received everolimus or zotarolimus eluting stents (68.2%), and even though the authors do mention the logistic regression analysis found no correlation between primary end point and type of stent or time of PCI, the results should take into account the number of patients.

The hypothesis stating that clopidogrel is superior to aspirin after post DES 12 month DAPT, calls for further analysis in a larger prospective, randomized study.

Courtesy of Dr. José Amadeo Guillermo Álvarez.

More articles by this author

How real are the adverse effects of statins? Evidence from randomized clinical trials

The safety of statins continues to be a subject of debate, partly due to the extensive list of adverse effects included in prescribing information,...

Is it safe to use negative chronotropic drugs early after TAVI?

TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing prevalence over the last decade, associated with...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...